Previous 10 | Next 10 |
In a briefing to a House committee, NIAID head Anthony Fauci says he is "hopeful" that the first patient will receive a coronavirus vaccine in a few weeks. More news on: Novavax, Inc., Emergent BioSolutions Inc., Sanofi, Healthcare stocks news, Stocks on the move, Read more ...
Today is looking like another journey down for U.S. equities on the heels of President Trump's address aimed at containing the coronavirus outbreak. His 30-day suspension of travel from much of Europe appears to have rattled investors. Other developments include the suspension of the remaind...
Penny Stocks To Watch As Coronavirus Cases Rise How bad is the spread coronavirus? It’s so bad that a conference held to discuss it was canceled because of it. The Council on Foreign Relations has canceled a roundtable called “Doing Business Under Coronavirus” scheduled fo...
Point Roberts, WA and Delta, BC - March 6, 2020 (Investorideas.com Newswire) Investorideas.com , a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories, including Vegan & Plant-based foods, biotech, mining and China-As...
DURHAM, NC / ACCESSWIRE / January 21, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate patients' immune systems against cancer, today announced the closing of its previously...
Thinly traded nano cap Heat Biologics ( HTBX -13.7% ) is down on almost 50% higher volume, a modest 552K shares, on the heels of its public offering of 20M common shares and 14-month warrants to purchase 1/2 of a common share at $0.385 at a combined price of $0.35. More news on: Heat B...
DURHAM, NC / ACCESSWIRE / January 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate patients' immune systems against cancer, today announced the pricing of an underwritte...
Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 Months DURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), presented additional positive Phase 2 interim top line data from Cohort A of the Company's Phase 2 trial of its...
DURHAM, NC / ACCESSWIRE / November 18, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced that top line data from its ongoing Phase 2 trial of HS-110 will be presen...
Heat Biologics (NASDAQ: HTBX ): Q3 GAAP EPS of -$0.18 misses by $0.05 . cash, cash equivalents and short-term investments of $15M Press Release More news on: Heat Biologics, Inc., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first...
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of ...
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice ...